China's healthcare sector has experienced a sharp rebound YTD, with the MSCI China Health Care Index surging by around 50%, according to JPMorgan's research report.In JPMorgan's estimate, the Hang Seng Healthcare Index (HSHCI) could reach or even exceed its 2022/23 highs, namely around 4,400-4,600.Related NewsGuotai Haitong Securities: Mainland Public Funds Continue to Increase Holdings in H Shrs in 2Q, Adding Stocks of Innovative Drugs, New Consumption & Div., Reducing Tech StocksAs the strong momentum may persist in the short term, JPMorgan believes that stocks with upcoming catalysts are well-positioned to continue outpacing the market. The broker preferred AKESO (09926.HK) +9.900 (+7.046%) Short selling $269.83M; Ratio 18.796% , INNOVENT BIO (01801.HK) +1.800 (+2.030%) Short selling $86.12M; Ratio 11.721% , and HENGRUI PHARMA (01276.HK) +1.100 (+1.519%) , while those with fewer catalysts included SKB BIO-B (06990.HK) +1.600 (+0.424%) Short selling $10.30M; Ratio 10.525% , REMEGEN (09995.HK) -0.850 (-1.218%) Short selling $3.94M; Ratio 0.945% and JUNSHI BIO (01877.HK) +1.050 (+4.183%) Short selling $13.04M; Ratio 5.853% .(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-22 12:25.)